TAKIYAH JONES: Open Payments
NPI 1013497924 · SMYRNA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$827 in 31 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $827
Food & beverage: $621Education: $206
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $300 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $134 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| ABBVIE INC. | 4 | $82 |
| Neurocrine BioSciences, Inc. | 2 | $65 |
| Alkermes, Inc. | 2 | $57 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: CAPLYTA, REXULTI, VRAYLAR, AUSTEDO XR, INGREZZA, ARISTADA, UZEDY, ABILIFY ASIMTUFII.
Industry payments across GA — which companies pay providers there.
